Avalo Therapeutics
AVTX
70 hedge funds and large institutions have $136M invested in Avalo Therapeutics in 2021 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 27 increasing their positions, 12 reducing their positions, and 15 closing their positions.
125% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 12
43% more call options, than puts
Call options by funds: $143K | Put options by funds: $100K
0% less ownership
Funds ownership: 0.03% → 0.02% (-0%)
7% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 15
1% less funds holding
Funds holding: 71 → 70 (-1)
22% less capital invested
Capital invested by funds: $176M → $136M (-$39.5M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$1.6M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$1.37M |
| 3 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$402K |
| 4 |
D.E. Shaw & Co
New York
|
+$336K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$180K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Asymmetry Capital Management
San Francisco,
California
|
-$1.17M |
| 2 |
Two Sigma Investments
New York
|
-$906K |
| 3 |
LCM
Laurion Capital Management
New York
|
-$720K |
| 4 |
Two Sigma Advisers
New York
|
-$678K |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$618K |
AVTX Hedge Fund Activity: Q4 2021 in Review
70 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Avalo Therapeutics (AVTX) for Q4 2021, worth a combined $136M — down 22% from $176M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of AVTX and 14 opened new positions — a net loss of 1 holder — while 12 trimmed existing stakes and 27 added.
The largest buyer was Soleus Capital Management, opening a new position worth an estimated $1.6M. The largest seller was Asymmetry Capital Management, exiting entirely with an estimated $1.17M sold.
- 70 institutional investors held Avalo Therapeutics (AVTX) as of Q4 2021, down from 71 in Q3 2021.
- Funds reported $136M of Avalo Therapeutics stock for Q4 2021, down 22% quarter-over-quarter.
- 14 funds opened new Avalo Therapeutics positions in Q4 2021 and 15 closed out, a net change of -1 holder.
- The largest Avalo Therapeutics buyer in Q4 2021 was Soleus Capital Management, an estimated $1.6M added.
- The largest Avalo Therapeutics seller in Q4 2021 was Asymmetry Capital Management, an estimated $1.17M sold.
Based on aggregated 13F filings for Q4 2021.